4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Retinoblastoma by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 47 ongoing clinical trials involving Retinoblastoma
Of the 47 trials,17 trials are in Phase II
Furthermore, 12 trials are in Phase III

Number of ongoing Clinical Trials (for drugs) involving Retinoblastoma by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Retinoblastoma, an Oncology condition. The largest number of ongoing clinical trials for Retinoblastoma is conducted in North America. Asia-Pacific and Europe are among some of the other prominent regions engaged in Retinoblastoma-related drug trials.

Memorial Sloan Kettering Cancer Center, Curie Institute and Sun Yat-sen University: The leading ongoing Retinoblastoma related clinical trial sponsors

Memorial Sloan Kettering Cancer Center, Curie Institute and Sun Yat-sen University are the top sponsors for Retinoblastoma-related ongoing clinical trials.

Seattle Children's Hospital, Y-mAbs Therapeutics Inc, Washington University School of Medicine and The Hospital for Sick Children are among other notable clinical trial sponsors involved in Retinoblastoma. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Retinoblastoma

Cyclophosphamide (Sendoxan), Carboplatin (Paraplatin, Carboplat, Paraplatine) and Anecortave acetate are among the key marketed drugs involving Retinoblastoma.

Cyclophosphamide (Sendoxan) is a derivative of nitrogen mustards, acts as an antineoplastic agent. It functions via DNA Synthesis Inhibitor mechanism of action. Cyclophosphamide is formulated as tablets for oral route of administration and as injectable solution for intravenous route of administration. Cyclophosphamide was first approved in 1958 and is marketed globally in the US, Denmark and Mexico by Baxter Healthcare Corp and Hikma Pharmaceuticals Plc.

Carboplatin (Paraplatin, Carboplat, Paraplatine), is an antineoplastic agent and chemotherapeutic agent. It functions via DNA Synthesis Inhibitor mechanism of action. Carboplatin is formulated as injection for intravenous use. Carboplatin was first approved in 1986 and is marketed globally in the US, Russia, China, Japan, France and Germany by several prominent pharma giants including Corden Pharma Switzerland LLC.